
Intellia Therapeutics, Inc.
NTLA·NASDAQ
Last updated as of 2026-04-02 07:02 EST. Stock price information is sourced from TradingView and reflects real-time market prices.
Insights
Calculator
News
NTLA stock price change
On the last trading day, NTLA stock closed at 12.82 USD, with a price change of 10.04% for the day.
Trade stock perpsTrending stocks
About Bitget
The world's first Universal Exchange (UEX), enabling users to trade not only cryptocurrencies, but also stocks, ETFs, forex, gold, and real-world assets (RWA).
Learn moreNTLA key data
Previous close12.82 USD
Market cap1.51B USD
Volume4.20M
P/E ratio-
Dividend yield (TTM)0.00%
Dividend amount-
Last ex-dividend date-
Last payment date-
EPS diluted (TTM)-3.83 USD
Net income (FY)−412.69M USD
Revenue (FY)67.67M USD
Next report dateApr 30, 2026
EPS estimate-
Revenue estimate13.57M USD USD
Shares float112.09M
Beta (1Y)1.72

Intellia Therapeutics, Inc. overview
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Sector
Health technology
Industry
Biotechnology
CEO
John M. Leonard
Headquarters
Cambridge
Website
intelliatx.com
Founded
2014
Employees (FY)
377
Change (1Y)
−26 −6.45%
Revenue / Employee (1Y)
179.50K USD
Net income / Employee (1Y)
−1.09M USD
NTLA stock price forecast
According to technical indicators for NTLA stock, the price is likely to fluctuate within the range of 13.90–16.91 USD over the next week. Market analysts predict that the price of NTLA stock will likely fluctuate within the range of 12.18–17.80 USD over the next months.
Based on 1-year price forecasts from 83 analysts, the highest estimate is 39.05 USD, while the lowest estimate is 10.66 USD.
For more information, please see the
NTLA stock price forecast
page.
Latest NTLA stock news
Ethereum Updates Today: ARK's Move Toward Ethereum Reflects Growing Institutional Adoption of Crypto Assets for Treasury Management
Bitget-RWA2025-11-14 02:08:10
Intellia gets FDA nod to resume gene therapy trial after safety pause
101 finance2026-01-27 13:39:10
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Finviz2026-02-19 12:33:03
Intellia Therapeutics to Participate in Upcoming Investor Conferences
Finviz2026-02-24 13:06:44
Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
Finviz2026-02-27 17:18:48
Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory
Finviz2026-02-28 15:09:06
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
Finviz2026-03-02 12:33:44
Biotechnology company Intellia Therapeutics announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its Phase 3 Magnitude trial for transthyretin amyloid cardiomyopathy (ATTR-CM).
老虎证券2026-03-02 12:41:06
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
Finviz2026-03-03 12:33:14
Roblox has started, Target receives an upgrade: Leading analyst recommendations from Wall Street
101 finance2026-03-04 14:48:37
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Finviz2026-03-06 21:06:48
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Finviz2026-03-06 21:06:48
ARK's TXG Trim Triggers Excessive Market Response—Gene-Editing Investments Suggest a Shift in Genomics Strategy
101 finance2026-03-21 21:36:57
Take the Zacks Strategy to Outperform the Market: Spotlight on LiveOne, Micron, and Clorox
101 finance2026-03-23 14:09:55
ARKK’s Subdued Week: Three Purchases, $15 Billion in Flows, and Market Price Effects
101 finance2026-03-23 17:15:55
Ethereum Updates Today: ARK's Move Toward Ethereum Reflects Growing Institutional Adoption of Crypto Assets for Treasury Management
Bitget-RWA2025-11-14 02:08:10
Intellia gets FDA nod to resume gene therapy trial after safety pause
101 finance2026-01-27 13:39:10
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Finviz2026-02-19 12:33:03
Intellia Therapeutics to Participate in Upcoming Investor Conferences
Finviz2026-02-24 13:06:44
Intellia Rises on Q4 Earnings & Revenue Beat, Focuses on Pipeline
Finviz2026-02-27 17:18:48
Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory
Finviz2026-02-28 15:09:06
